MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Psychogenic movement disorders(PMD): Treatment"

  • 2019 International Congress

    Opinions and clinical practices related to diagnosing and managing patients with functional (psychogenic) movement disorders: from 2009 to 2019

    K. Lafaver, D. Bega, M. Hallett, A. Lang, S. Lidstone, C. Maurer, F. Morgante, D. Perez, C. Stephen, J. Stone, T. Teodoro, A. Wu, A. Dwivedi, A. Espay (Louisville, KY, USA)

    Objective: (1) To examine current opinion and clinical practices related to diagnosis and management of Functional Movement Disorders (FMD); and (2) to determine if practice…
  • 2019 International Congress

    Botulinum Neurotoxin (BoNT) treatment in functional movement disorders: an extended follow up

    J. Dijk, M. Tijssen, J. Koelman, Y. Dreissen, F. Lambert (Groningen, Netherlands)

    Objective: To assess the long term effect of treatment with botulinum neurotoxin (BoNT) in patients with functional jerky or tremorous movement disorders. Background: Treatment options for…
  • 2018 International Congress

    Neuropsychiatric disorders in observed patients with Parkinson’s disease

    S. Lukmonov, D. Tolibov (Tashkent, Uzbekistan)

    Objective: Parkinson's disease (PD), - chronic progressive disease of the brain from the degeneration of the nigrostriatal neurons in the basal ganglia and impaired function.…
  • 2017 International Congress

    Botulinum Neurotoxin (BoNT) for treatment of functional (psychogenic) jerky movement disorders: a randomized placebo-controlled clinical trial

    Y. Dreissen, J. Dijk, J. Gelauff, E. Zoons, M. Contarino, R. Zutt, B. Post, D. van Poppelen, A. Munts, J. Speelman, R. de Haan, J. Koelman, M. Tijssen (Amsterdam, Netherlands)

    Objective: To assess the effectiveness of botulinum neurotoxin (BonT) in patients with functional jerky movement disorders Background: At least 2–9% of patients seen in movement…
  • 2017 International Congress

    Treatment of Functional Neurological Disorders: Towards Expert Consensus Led Guidelines for the American Neuropsychiatric Association Committee for Research

    O. Ghaffar, M. Modirrousta, C. LaFrance, N. Williams, R. Shura, S. Ducharme, V. Voon (Whitby, ON, Canada)

    Objective: To develop evidence-based, expert consensus recommendations for the treatment of functional neurological disorders (FND) on behalf of the ANPA Committee for Research. Background: FND…
  • 2016 International Congress

    Attention to action: Common to both conversion (psychogenic) and Parkinsonian (neurogenic) motor speech disorders

    S. Sapir (Haifa, Israel)

    Objective: To review and present a common abnormality --- attention to action--- underlying Parkinsonian and conversion speech disorders. Background: Conversion speech disorders are characterized by…
  • 2016 International Congress

    Cognitive behavioural thrapy and adiunctive physical therapy for functional movement disorders

    R. Erro, M. Tinazzi, C. Dallocchio (London, United Kingdom)

    Objective: To test the feasibility and efficacy of Cognitive Behavioural Therapy (CBT) and Adjunctive Physical Therapy (APA) APA in Functional Movement Disorders (FMD). Background: Functional…
  • 2016 International Congress

    Transcranial versus root repeated magnetic stimulation as a treatment of psychogenic movement disorders

    B. Garcin, C. Hubsch, L. Lliescu, L. Naccache, M. Vidailhet, E. Fournier, F. Mesrati, E. Roze, B. Degos (Paris, France)

    Objective: To determine whether the beneficial effect of repeated transcranial magnetic stimulation (rTMS) in psychogenic movement disorders (PMDs) is the consequence of a cortical functioning…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • #24970 (not found)
  • Comorbid Normal Pressure Hydrocephalus with Parkinson’s disease: a call for clinical awareness
  • Common mistakes in the MoCA test in patients with Parkinson’s Disease in Kyrgyzstan
  • Effect of marijuana on Essential Tremor: A case report
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley